BioCardia (BCDA) CEO Peter Altman Buys 5,400 Shares

What Happened Peter Altman, President, CEO and Director of BioCardia, acquired 5,400 shares of BCDA in an open‑market purchase on August 17, 2026. The filing reports a weighted average price of $0.93 per share for a total cost of $5,022. This was a purchase (transaction code P), which some investors view as a more informative insider action than routine sales.

Key Details

• Transaction date: 2026-08-17 (reported on Form 4 filed 2026-08-18). Filing appears timely (not marked late).
• Trade details: 5,400 shares purchased; weighted average price $0.93; total reported value $5,022.
• Price range: trades executed at prices between $0.92 and $0.97 per share (weighted average reported). See footnote F1 for breakdown offer.
• Shares owned after transaction: not disclosed in this filing.
• Footnote: F1 states the transaction was executed in multiple trades at $0.92–$0.97; the filer can provide the per‑trade breakdown on request.
• Transaction code: P = Purchase (open market). No indication of option exercise, gift, tax withholding, or 10b5‑1 plan in this filing.

Context This was a straightforward open‑market purchase by the company’s CEO for a small total amount (~$5k). Purchases by executives can be interpreted by some investors as a positive signal, but filings alone don’t reveal motivation. If you want the precise per‑trade pricing, the filer has offered to provide those details to the SEC or issuer on request.